MSK-IMPACT A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology

Publication date: Available online 20 March 2015 Source:The Journal of Molecular Diagnostics Author(s): Donavan T. Cheng , Talia Mitchell , Ahmet Zehir , Ronak H. Shah , Ryma Benayed , Aijazuddin Syed , Raghu Chandramohan , Zhen Yu Liu , Helen H. Won , Sasinya N. Scott , A. Rose Brannon , Catherine O'Reilly , Justyna Sadowska , Jacklyn Casanova , Angela Yannes , Jaclyn Hechtman , Jinjuan Yao , Wei Song , Dara Ross , Alifya Oultache , Snjezana Dogan , Laetitia Borsu , Meera Hameed , Khedoudja Nafa , Maria E. Arcila , Marc Ladanyi , Michael F. Berger The identification of specific genetic alterations as key oncogenic drivers and the development of targeted therapies are together transforming clinical oncology and creating a pressing need for increased breadth and throughput of clinical genotyping. Next-generation sequencing assays allow the efficient and unbiased detection of clinically actionable mutations. To enable precision oncology in patients with solid tumors, we developed MSK-IMPACT, a hybridization capture-based next-generation sequencing assay for targeted deep sequencing of all exons and selected introns of 341 key cancer genes in formalin-fixed, paraffin-embedded tumors. Barcoded libraries from patient-matched tumor and normal samples were captured, sequenced, and subjected to a custom analysis pipeline to identify somatic mutations. Sensitivity, specificity, reproducibility of MSK-IMPACT were assessed through extensive analytical vali...
Source: The Journal of Molecular Diagnostics - Category: Pathology Source Type: research